



PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/575,938

Filing Date

4/13/06

First Named Inventor

Thoene

Art Unit

1654

Examiner Name

Unassigned

Attorney Docket Number

TUL5AUSA

ENCLOSURES (Check all that apply)☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Reply to Missing Parts/
Incomplete Application☐Reply to Missing Parts
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a
Provisional Application☐

Power of Attorney, Revocation

☐

Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐

Landscape Table on CD

☐

After Allowance Communication to TC

☐Appeal Communication to Board
of Appeals and Interferences☐Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☐Other Enclosure(s) (please identify
below):

Remarks

Customer No. 00270

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Howson & Howson LLP

Signature

Printed name

Mary E. Bak

Date

Feb 27, 2007

Reg. No.

31,215

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Summer Uchin

Date

2/27/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



TUL5AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/575,938 Confirmation No.: 7083
Applicant : Thoene
Filed : April 13, 2006
TC/A.U. : 1654
Examiner :
Customer No. : 00270
Title : METHODS AND COMPOSITIONS FOR TREATING
CANCER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. The forms are attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application, before the receipt of a first Office Action. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account No. 08-3040.

REMARKS

Listed below are documents cited in the International Search Report dated July 24, 2006 in the corresponding International Patent Application No. PCT/US04/32305. A copy of the Report is enclosed, together with copies of these documents.

- (i) PISONI et al., "Description of a Selection Method Highly Cytotoxic for Cystinotic Fibroblasts but not Normal Human Fibroblasts", Somatic Cell Molecular Genetics, 18(1):1-6 (January 1992)
- (ii) OIRY et al., "Synthesis and Radioprotective Activity of Dipeptide Cysteamine and Cystamine Derivatives", J. Med. Chem. 32:297-301 (1989)

The month of publication for documents AAU, BX, and BZ could not be determined. The years of publication for these documents are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not in issue (MPEP 609).

Applicants also noted that document AAX was made available to attendees at the American Society of Human Genetics, 53rd Annual Meeting on November 4-8, 2003 in Los Angeles, CA. Applicants were also advised that this abstract was contained in a program/abstract volume, which was mailed to registrants on September 19, 2003.

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached forms during the course of examination of this application.

Respectfully submitted,

HOWSON & HOWSON
Attorneys for Applicants

By: Mary E. Bak
Mary E. Bak
Registration No. 31,215
Suite 210
501 Office Center Drive
Fort Washington, PA 19034
Telephone: 215-540-9200
Telefacsimile: 215-540-5818



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/575,938
				Filing Date	4/13/2006
				First Named Inventor	Thoene
				Art Unit	1654
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	TUL5AUSA

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	AR	AFFORD et al., "Demystified...Apoptosis", J. Clin. Pathol.: Mol. Pathol., 53:55-63 (April 2000)		
	AS	BUSCHINI et al., "Saccharomyces cerevisiae as an Eukaryotic Cell Model to Assess Cytotoxicity and Genotoxicity of Three Anticancer Anthraquinones", Mutagenesis, 18(1):25-36 (January 2003)		
	AT	COLEMAN et al., "Membrane Blebbing During Apoptosis Results from Caspase-Mediated Activation of ROCK I", Nature Cell Biol., 3:339 (April 2001)		
	AU	CHU et al., "PKC Isozyme S-cysteinylation by Cystine Stimulates the Pro-Apoptotic Isozyme PKCδ and Inactivates the Ocogenic Isozyme PKCε", Carcinogenesis, 24(2):317-325 (February 2003)		
	AV	CHU et al., "Cellular Protein Kinase C Isozyme Regulation by Exogenously Delivered Physiological Disulfides - Implications of Oxidative Protein Kinase C Regulation to Cancer Prevention", Carcinogenesis, 25(4):585-596 (April 2004; E Pub: December 4, 2003)		
	AW	HELIP-WOOLEY et al., "Expression of CTNS Alleles: Subcellular Localization and Aminoglycoside Correction in Vitro", Mol. Genetics and Metabol., 75:128-133 (February 2002)		
	AX	KANDUC et al., "Cell Death: Apoptosis Versus Necrosis (Review)", Int. J. Oncol., 21:165-170 (July 2002)		
	AY	KANG et al., "A Role for Uric Acid in the Progression of Renal Disease", J. Am. Soc. Nephrol., 13:2888-2897 (December 2002)		
	AZ	KAUFMANN et al., "Induction of Apoptosis by Cancer Chemotherapy", Exp. Cell. Res., 256:42-49 (April 10, 2000)		
	AAR	LEMONS et al., "Elevated Temperature Produces Cystine Depletion of Cystinotic Fibroblasts", Biochim. et Biophys. Acta 884:429-434 (December 10, 1986)		
	AAS	OIRY et al., "Synthesis and Radioprotective Activity of Dipeptide Cysteamine and Cystamine Derivatives", J. Med. Chem. 32:297-301 (February 1989)		
	AAT	OSHIMA et al., "Cystine Metabolism in Human Fibroblasts", J. Biol. Chem., 251(14):4287-4293 (July 25, 1976)		
	AAU	PARK et al., "Cystinotic Fibroblasts Display Aberrant Apoptosis", Am. J. Hum. Genetics, 69(4), Abstract 1774 (2001)		
	AAV	PARK et al., "Potential Role of Apoptosis in Development of the Cystinotic Phenotype", Pediatr. Nephrol., 20:441-446 (April 2005 - E Pub: December 28, 2004)		
	AAW	PARK et al., "Lysosomal Cystine Storage Augments Apoptosis in Cultured Human Fibroblasts and Renal Tubular Epithelial Cells", J. Am. Soc. Nephrol., 13:2878-2887 (December 2002)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/575,938
				Filing Date	4/13/2006
				First Named Inventor	Thoene
				Art Unit	1654
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	TUL5AUSA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AAX	PARK et al., "Mouse L929 Fibroblasts do not Display Increased Apoptosis Following Lysosomal Cystine Loading with CDME", American Society of Human Genetics, 53 rd Annual Meeting, Los Angeles, CA, Biochemical Genetics Poster #42 (2003)	
	AAY	PISONI et al., "Detection and Characterization of a Transport System Mediating Cysteamine Entry into Human Fibroblast Lysosomes", J. Biol. Chem., 270(3):1179-1184 (January 20, 1995)	
	AAZ	PISONI et al., "Important Differences in Cationic Amino Acid Transport by Lysosomal System c and System y ⁺ of the Human Fibroblast", J. Biol. Chem., 262(31):15011-15018 (November 5, 1987)	
	BR	PISONI et al., "Detection and Characterization of Carrier-Mediated Cationic Amino Acid Transport in Lysosomes of Normal and Cystinotic Human Fibroblasts", J. Biol. Chem., 260(8):4791-4798 (April 25, 1985)	
	BS	PISONI et al., "Description of a Selection Method Highly Cytotoxic for Cystinotic Fibroblasts but not Normal Human Fibroblasts", Somatic Cell Molecular Genetics, 18(1):1-6 (January 1992)	
	BT	PISONI et al., "Utilization of Mercaptoethylgluconamide for Depleting Human Cystinotic Fibroblasts of their Accumulated Lysosomal Cystine", 26(1): 73-76 (July 1989)	
	BU	SAUTER et al., "Consequences of Cell Death: Exposure to Necrotic Tumor Cells, but Not Primary Tissue Cells or Apoptotic Cells, Induces the Maturation of Immunostimulatory Dendritic Cells", J. Exp. Med., 191(3): 423 (February 7, 2000)	
	BV	SCHNEIDER et al., "Ineffectiveness of Ascorbic Acid Therapy in Nephropathic Cystinosis", N. Engl. J. Med., 300:756 (April 5, 1979)	
	BW	SHIOKAWA et al., "Involvement of DNase γ in Apoptosis Associated with Myogenic Differentiation of C2C12 Cells", J. Biol. Chem., 277(34):31031-31037 (August 23, 2002)	
	BX	THOENE et al., "Advances in Understanding the Pathophysiology of Cystinosis and Lysosomal Biogenesis", Cystinosis Research Network Newsletter, Fall 2003	
	BY	THOENE et al., "Mutations of CTNS Causing Intermediate Cystinosis", Mol. Genetics Metabol., 67:283-293 (August 1999)	
	BZ	THOENE et al., "Cystine Depletion of Cystinotic Cells by Aminoethiols", Proc. Roy. Soc. Med., 70(3):37-40 (1977)	
	BBR	THOENE et al., "Inhibitors of Protein Synthesis Also Inhibit Lysosomal Proteolysis Studies Using Cystinotic Fibroblasts", J. Clin. Invest., 75:370-376 (February 1985)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

(Use as many sheets as necessary)

Attorney Docket Number	TULSAUSA
------------------------	----------

Sheet	3	of	3
-------	---	----	---

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.